CYTOF Altamira Therapeutics Ltd. IFRS Annual reports only
Pharmaceutical Preparations · OTC · SEC CIK 1601936 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2024*2024-12-31 · USD | FY20232023-12-31 · CHF |
|---|---|---|
| Income statement | ||
| Revenue | — | 379 |
| Cost of revenue | — | 33,967 |
| Gross profit | — | -33,588 |
| R&D expense | $3.73M | 3.04M |
| SG&A expense | $3.20M | 3.14M |
| Operating income | -$6.85M | -5.92M |
| Interest expense | $0 | 1.01M |
| Pretax income | -$8.46M | -7.27M |
| Net income | -$8.46M | -3.87M |
| EPS (basic) | -2.99 | -7.88 |
| EPS (diluted) | -2.99 | -7.88 |
| Weighted avg. shares (diluted) | 451,555 | 41,803 |
| Balance sheet | ||
| Cash & equivalents | $998,624 | 617,409 |
| Current assets | $1.54M | 1.22M |
| PP&E, netmay include right-of-use assets (IFRS) | $100,000 | 1 |
| Intangibles | $4.63M | 3.89M |
| Total assets | $8.65M | 7.69M |
| Current liabilities | $1.16M | 888,914 |
| Total liabilities | $2.09M | 1.24M |
| Shareholders' equity | $6.57M | 6.46M |
| Shares outstanding | 4.66M | 1.48M |
| Cash flow statement | ||
| Operating cash flow | -$6.11M | -$12.81MUSD |
| Capital expenditure | $103,087 | — |
| Free cash flow | -$6.22M | — |
| Investing cash flow | -$115,341 | 1.44M |
| Financing cash flow | $6.51M | 10.62M |
| Stock-based compensation | $532,081 | 379,414 |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.